Guardant Health Stock Price, News & Analysis

Guardant Health, Inc. (NASDAQ: GH) announced it will release its third quarter 2022 financial results on November 3, 2022, after market close. The company will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can listen live through the company's website, with an archived replay available post-event. Guardant Health focuses on precision oncology and offers a variety of proprietary tests aimed at improving patient outcomes and reducing healthcare costs.

Guardant Health (NASDAQ: GH) has launched GuardantINFINITY™, a next-generation liquid biopsy assay that enhances tumor analysis by combining over 800 gene panel insights with exome-wide methylation detection. This innovative platform allows researchers to gain comprehensive insights into tumor biology and patient immune responses through a simple blood draw, eliminating the need for further sample collection. The assay supports various applications, including therapy selection and monitoring, marking a significant advancement in precision oncology.

Guardant Health (Nasdaq: GH) announced new data from its blood tests to be presented at the 2022 ESMO Congress (September 9-13, Paris). It includes findings on liquid biopsy tests to identify biomarkers, predict therapy response, and detect resistance mechanisms in late-stage cancers. Highlights involve oral and poster presentations showcasing significant findings like genomic resistance mechanisms and clinical potential of ctDNA for monitoring treatments. These advancements aim to foster better understanding and outcomes in cancer therapy.

Guardant Health (Nasdaq: GH) has announced an expanded collaboration with Merck KGaA to advance precision oncology through its GuardantINFORM real-world evidence platform. This partnership aims to speed up therapy development for crucial cancer indications with high unmet needs. Data scientists from Guardant Health will work alongside Merck KGaA on various initiatives using genomic and clinical information from over 225,000 cancer patients. This collaboration emphasizes Guardant Health's commitment to improving patient outcomes and accelerating the availability of innovative cancer treatments.

Guardant Health, a precision oncology leader, will participate in the Morgan Stanley Global Healthcare Conference in New York City on September 12, at 8:10 a.m. ET. The event will include a fireside chat, accessible via a live and archived webcast on the company’s website. Guardant Health specializes in cancer diagnostics, leveraging proprietary tests like the Guardant360 and Guardant Reveal to enhance patient outcomes and reduce healthcare costs. Visit guardanthealth.com for more information.

Guardant Health Inc. (Nasdaq: GH) has expanded the availability of its innovative blood test, Guardant Reveal™, which detects minimal residual disease in colorectal, breast, and lung cancers without the need for a tissue biopsy. This test enables early identification of patients at higher risk for recurrence post-surgery, promising improved management of early-stage cancer. The Guardant Reveal test can be initiated three weeks post-surgery and outperforms traditional monitoring tools in predicting disease recurrence.

Guardant Health has received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This test identifies patients who may benefit from the antibody drug conjugate ENHERTU. The Guardant360 CDx assay will enable oncologists to obtain comprehensive genomic results from a blood sample within a week, marking a significant advancement over traditional tissue biopsies. The HER2 mutations drive 2-4% of non-squamous NSCLC, representing a critical step for targeted cancer therapies.

Guardant Health (NASDAQ: GH) will participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA. The management team is scheduled for a fireside chat on Wednesday, August 10, at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access a live and archived webcast via the company's website. Guardant Health focuses on precision oncology, providing proprietary tests and analytics to improve cancer care. Its offerings include the Guardant360® suite for advanced cancer and the Shield™ test for cancer screening.

Guardant Health and Blueprint Medicines presented new data at the IASLC 2022 World Conference on Lung Cancer, revealing that the EGFR C797X mutation is a prevalent resistance mechanism to osimertinib for advanced non-small cell lung cancer (NSCLC) patients. The cumulative incidence of this mutation was found to be 12.5% after first-line treatment. The collaboration utilized the GuardantINFORM platform to analyze data from over 2,000 patients, emphasizing the need for next-generation EGFR inhibitors to combat C797X-driven resistance in NSCLC.